ESC 365 - The clinical implementation of a de-escalation strategy using CYP2C19 genotyping in patients with an acute coronary syndrome: insights from the FORCE-ACS registry

ESC Professional Premium Access

The clinical implementation of a de-escalation strategy using CYP2C19 genotyping in patients with an acute coronary syndrome: insights from the FORCE-ACS registry

Session: Pharmacogenetics: a tool to guide clinical decisions

Topic: Pharmacogenetics

Speaker: Doctor J. Azzahhafi (Nieuwegein, NL)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Jaouad Azzahhafi

St Antonius Hospital, Nieuwegein (Netherlands (The))

0 follower

4 more presentations in this session

Genome-wide association study of amidoarone-induced hypothyroidism

Speaker: Mr S. Rand (Copenhagen, DK)

Arg389Gly beta-1-adrenergic receptor polymorphism determines neutrophil-stunning-associated cardioprotection by metoprolol

Speaker: Mr A. Clemente Moragon (Madrid, ES)

SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort

Speaker: Doctor E. Magavern (London, GB)

Impact of CYP2C19 genotype status on clinical outcomes in patients with symptomatic coronary artery disease, stroke, and peripheral arterial disease

Speaker: Ms D. Maas (Nijmegen, NL)

Access the full session

Pharmacogenetics: a tool to guide clinical decisions

Speakers: Doctor J. Azzahhafi, Mr S. Rand, Mr A. Clemente Moragon, Doctor E. Magavern, Ms D. Maas

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources